A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53 -mutant ovarian cancer
Oza, Amit M, Estevez-Diz, Maria D P, Grischke, Eva-Maria, Hall, Marcia, Marmé, Frederik, Provencher, Diane M., Uyar, Denise S., Weberpals, Johanne I, Wenham, Robert M., Laing, Naomi, Tracy, Michael,Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-20-0219
Date:
July, 2020
File:
PDF, 631 KB
2020